摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-fluorophenyl)-5-isopropylbenzo[d]oxazole

中文名称
——
中文别名
——
英文名称
2-(4-fluorophenyl)-5-isopropylbenzo[d]oxazole
英文别名
2-(4-Fluorophenyl)-5-isopropyl-1,3-benzoxazole;2-(4-fluorophenyl)-5-propan-2-yl-1,3-benzoxazole
2-(4-fluorophenyl)-5-isopropylbenzo[d]oxazole化学式
CAS
——
化学式
C16H14FNO
mdl
——
分子量
255.292
InChiKey
NXMLIPWMHVLLMJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    26
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为产物:
    描述:
    3-(4-Fluoro-phenyl)-2,2-dimethyl-3-oxo-propionic acid methyl ester 在 1,2-双(叔丁基氨基)乙烷盐酸羟胺potassium tert-butylate 、 copper diacetate 、 sodium acetate 作用下, 以 1,2-二氯乙烷 为溶剂, 反应 12.0h, 生成 2-(4-fluorophenyl)-5-isopropylbenzo[d]oxazole
    参考文献:
    名称:
    苯酚和环肟铜催化合成苯并恶唑
    摘要:
    报道了一种由游离酚和环肟酯催化直接合成苯并恶唑的方法。温和的反应条件耐受两种底物上的各种吸电子和给电子官能团,以中等至良好的产率提供苯并恶唑。使用该协议,证明了在一个或两个步骤中大规模合成Ezutromid和Flunoxaprofe 。提出了一种催化机制,包括通过内球电子转移和随后的环化进行铜催化胺化。
    DOI:
    10.1021/acs.orglett.1c04322
点击查看最新优质反应信息

文献信息

  • NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    申请人:EARL Richard A.
    公开号:US20100093671A1
    公开(公告)日:2010-04-15
    The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders.
    该发明描述了新型亚硝酰化非甾体抗炎药(NSAIDs)及其药学上可接受的盐,并且描述了至少包含一种亚硝酰化NSAID和可选的至少一种化合物的新型组合物,该化合物捐赠、转移或释放一氧化氮,刺激内源性一氧化氮的合成,提高内源性内皮源性松弛因子的水平或是一氧化氮合酶的底物,并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID和至少一种化合物的新型组合物,该化合物捐赠、转移或释放一氧化氮,提高内源性内皮源性松弛因子的水平,刺激内源性一氧化氮的合成或是一氧化氮合酶的底物,并/或至少包含一种治疗剂。该发明还提供了至少包含一种亚硝酰化NSAID,可选的至少一种一氧化氮供体和/或至少一种治疗剂的新型试剂盒。该发明还提供了治疗炎症、疼痛和发热的方法;治疗胃肠道疾病的方法;促进伤口愈合的方法;治疗和/或预防使用非甾体抗炎化合物导致的胃肠道、肾脏和/或呼吸道毒性的方法;治疗炎症性疾病状态和/或疾病的方法;以及治疗和/或预防眼科疾病和/或疾病的方法。
  • Nucleic Acids Encoding Nitrilases
    申请人:DESANTIS Grace
    公开号:US20110263839A1
    公开(公告)日:2011-10-27
    The invention relates to nitrilases and to nucleic acids encoding the nitrilases. In addition methods of designing new nitrilases and method of use thereof are also provided. The nitrilases have increased activity and stability at increased pH and temperature.
    该发明涉及腈水解酶以及编码腈水解酶的核酸。此外,还提供了设计新腈水解酶的方法和使用方法。该腈水解酶在高pH和高温下具有增强的活性和稳定性。
  • Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use
    申请人:Earl Richard
    公开号:US20110098253A1
    公开(公告)日:2011-04-28
    The invention also provides methods for treating inflammation, pain and fever; for treating gastrointestinal disorders; for facilitating wound healing; for treating and/or preventing gastrointestinal, renal and/or respiratory toxicities resulting from the use of nonsteroidal antiinflammatory compounds; for treating inflammatory disease states and/or disorders; and for treating and/or preventing ophthalmic diseases and/or disorders comprising administration of novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent.
    该发明还提供了治疗炎症、疼痛和发热的方法;治疗胃肠道疾病的方法;促进伤口愈合的方法;治疗和/或预防非甾体类抗炎化合物使用引起的胃肠道、肾脏和/或呼吸道毒性的方法;治疗炎症性疾病状态和/或疾病的方法;以及治疗和/或预防眼科疾病和/或疾病的新组合物的给药方法,该组合物包括至少一种硝化的非甾体类抗炎药,以及可选地至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂。
  • MANUFACTURING PROCESS FOR NO-DONATING COMPOUNDS SUCH AS NO-DONATING DICLOFENAC
    申请人:ANDERSSON Johan
    公开号:US20090170934A1
    公开(公告)日:2009-07-02
    The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active NO-donating compounds. The invention further relates to a substantially crystalline form of NO-donating NSAIDs, especially 2-[2-(nitrooxy)ethoxy]ethyl 2-[(2,6-dichlorophenyl)amino]phenyl}acetate, the preparation thereof and to pharmaceutical formulations containing said crystalline form and to the use of said crystalline form in the preparation of a medicament.
    本发明涉及一种使用磺化中间体制备NO供体化合物的新工艺。该发明涉及其中制备的适用于NO供体化合物大规模生产的新中间体。本发明还涉及使用新中间体制造药用活性NO供体化合物。此外,本发明还涉及NO供体NSAIDs的实质晶体形式,特别是2-[2-(硝氧基)乙氧基]乙基2-[(2,6-二氯苯基)氨基]苯基}乙酸酯的制备,以及含有该晶体形式的制药配方和在制备药物时使用该晶体形式的用途。
  • Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds And Methods Of Use
    申请人:Kim Ronald M.
    公开号:US20090209564A1
    公开(公告)日:2009-08-20
    Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
    本文披露了一种胰高血糖素受体拮抗剂化合物。这些化合物可用于治疗2型糖尿病及相关疾病。同时还包括制药组合物和治疗方法。
查看更多

同类化合物

伊莫拉明 (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5-氨基-1,3,4-噻二唑-2-基)甲醇 齐墩果-2,12-二烯[2,3-d]异恶唑-28-酸 黄曲霉毒素H1 高效液相卡套柱 非昔硝唑 非布索坦杂质Z19 非布索坦杂质T 非布索坦杂质K 非布索坦杂质E 非布索坦杂质67 非布索坦杂质65 非布索坦杂质64 非布索坦杂质61 非布索坦代谢物67M-4 非布索坦代谢物67M-2 非布索坦代谢物 67M-1 非布索坦-D9 非布索坦 非唑拉明 雷西纳德杂质H 雷西纳德 阿西司特 阿莫奈韦 阿米苯唑 阿米特罗13C2,15N2 阿瑞匹坦杂质 阿格列扎 阿扎司特 阿尔吡登 阿塔鲁伦中间体 阿培利司N-1 阿哌沙班杂质26 阿哌沙班杂质15 阿可替尼 阿作莫兰 阿佐塞米 镁(2+)(Z)-4'-羟基-3'-甲氧基肉桂酸酯 锌1,2-二甲基咪唑二氯化物 铵2-(4-氯苯基)苯并恶唑-5-丙酸盐 铬酸钠[-氯-3-[(5-二氢-3-甲基-5-氧代-1-苯基-1H-吡唑-4-基)偶氮]-2-羟基苯磺酸基][4-[(3,5-二氯-2-羟基苯 铁(2+)乙二酸酯-3-甲氧基苯胺(1:1:2) 钠5-苯基-4,5-二氢吡唑-1-羧酸酯 钠3-[2-(2-壬基-4,5-二氢-1H-咪唑-1-基)乙氧基]丙酸酯 钠3-(2H-苯并三唑-2-基)-5-仲-丁基-4-羟基苯磺酸酯 钠(2R,4aR,6R,7R,7aS)-6-(2-溴-9-氧代-6-苯基-4,9-二氢-3H-咪唑并[1,2-a]嘌呤-3-基)-7-羟基四氢-4H-呋喃并[3,2-D][1,3,2]二氧杂环己膦烷e-2-硫醇2-氧化物 野麦枯 野燕枯 醋甲唑胺